Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
801 to 820 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Advances and limitations for the treatment of spinal muscular atrophy. | BMC Pediatr | 2022 | 36329412 | PubTator, text mining | PubMed |
| Bridging the Gap: Gene Therapy in a Patient With Spinal Muscular Atrophy Type 1. | Neurology | 2022 | 36319109 | PubTator, text mining | PubMed |
| Utilization and Potential of RNA-Based Therapies in Cardiovascular Disease. | JACC Basic Transl Sci | 2022 | 36317129 | PubTator, text mining | PubMed |
| Gene Therapy for Neuromuscular Diseases: Health Economic Challenges and Future Perspectives. | J Neuromuscul Dis | 2022 | 36314216 | PubTator, text mining | PubMed |
| Research advances in treatment methods and drug development for rare diseases. | Front Pharmacol | 2022 | 36313320 | PubTator, text mining | PubMed |
| Clinical and Electrophysiological Changes in Pediatric Spinal Muscular Atrophy after 2 Years of Nusinersen Treatment. | Pharmaceutics | 2022 | 36297509 | PubTator, text mining | PubMed |
| Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy. | Genes (Basel) | 2022 | 36292797 | PubTator, text mining | PubMed |
| Alternative Splicing in Human Physiology and Disease. | Genes (Basel) | 2022 | 36292705 | PubTator, text mining | PubMed |
| SMN Is Physiologically Downregulated at Wild-Type Motor Nerve Terminals but Aggregates Together with Neurofilaments in SMA Mouse Models. | Biomolecules | 2022 | 36291733 | PubTator, text mining | PubMed |
| Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy. | Biomolecules | 2022 | 36291640 | PubTator, text mining | PubMed |
| Cancer cells hijack RNA processing to rewrite the message. | Biochem Soc Trans | 2022 | 36282006 | PubTator, text mining | PubMed |
| Changes in the Incidence of Infantile Spinal Muscular Atrophy in Shikoku, Japan between 2011 and 2020. | Int J Neonatal Screen | 2022 | 36278622 | PubTator, text mining | PubMed |
| Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study. | Orphanet J Rare Dis | 2022 | 36274155 | PubTator, text mining | PubMed |
| Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12. | Nat Commun | 2022 | 36271053 | PubTator, text mining | PubMed |
| Scalable detection of technically challenging variants through modified next-generation sequencing. | Mol Genet Genomic Med | 2022 | 36251442 | PubTator, text mining | PubMed |
| Natural antisense transcripts as drug targets. | Front Mol Biosci | 2022 | 36250017 | PubTator, text mining | PubMed |
| Exploratory evaluation of an eye-tracking system in patients with advanced spinal muscular atrophy type I receiving nusinersen. | Front Neurol | 2022 | 36247789 | PubTator, text mining | PubMed |
| Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. | Lancet Neurol | 2022 | 36244364 | PubTator, text mining | PubMed |
| Oligonucleotide-Recognizing Topoisomerase Inhibitors (OTIs): Precision Gene Editors for Neurodegenerative Diseases? | Int J Mol Sci | 2022 | 36232843 | PubTator, text mining | PubMed |
| Adults with spinal muscular atrophy: a large-scale natural history study shows gender effect on disease. | J Neurol Neurosurg Psychiatry | 2022 | 36220341 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=41